The use of atopic dermatitis and asthma treatment Dupixent (dupilumab) could be expanding also in South Korea to be administered to children.

A pharmaceutical industry source reported Sanofi Genzyme has submitted an indication expansion application last year on Dupixent to be indicated for a ‘treatment in pediatric patients aged six through 11 with severe case of atopic dermatitis and underlying condition of various type 2 inflammations,’ and a ‘treatment in patients with type 2 inflammatory asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).’ The approval decision would be made within the first quarter of the year.

A Phase III trial has reportedly confirmed the efficacy